Analystreport

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) had its price target lowered by analysts at Needham & Company LLC from $50.00 to $48.00. They now have a "buy" rating

KalVista Pharmaceuticals, Inc.  (KALV) 
Last kalvista pharmaceuticals, inc. earnings: 3/10 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.kalvista.com